|Mr. Ron Squarer BSc (Biochemistry), MBA||Chief Exec. Officer and Director||1.06M||N/A||50|
|Mr. Andrew R. Robbins||Chief Operating Officer||684.38k||N/A||41|
|Dr. Victor Sandor M.D., C.M||Chief Medical Officer||745.35k||N/A||51|
|Mr. Jason Haddock||Chief Financial Officer||N/A||N/A||47|
|Dr. Nicholas A. Saccomano Ph.D.||Chief Scientific Officer||N/A||N/A||58|
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The companys drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. Its drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer. In addition, the company is developing ARRY-797, a p38 inhibitor, which is in Phase II clinical trials for Lamin A/C-related dilated cardiomyopathy; Motolimod/VTX-2337, a Toll-like receptor that is under Phase II clinical studies for cancer; and Prexasertib/LY2606368, a CHK-1 inhibitor, which is in Phase II clinical studies for cancer, as well as ARRY-382, a CSF1R inhibitor that is under Phase I/II clinical trial to treat cancer. Further, it is developing GDC-0575, a CHK-1 inhibitor that is in Phase Ib clinical trial for the treatment of cancer; LOXO-292, a RET inhibitor, which is under Phase I clinical trials to treat cancer; and LOXO-195, a NTRK inhibitor that is under Phase I clinical trials to treat cancer. Array BioPharma Inc. has a collaboration agreement with Amgen, Asahi Kasei Pharma Corporation, Loxo Oncology, and Mirati Therapeutics, Inc. The company was founded in 1998 and is headquartered in Boulder, Colorado.
Array BioPharma Inc.’s ISS Governance QualityScore as of August 1, 2017 is 8. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 8; Compensation: 10.